ERS Genomics signs CRISPR deal with Lonza
ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.
Invisalign creator sues competitor for patent infringement
Align Technology, a manufacturer of 3D digital scanners and founder of the orthodontic brand Invisalign, has filed a patent infringement suit against rival company 3Shape.
Biotech firm to use Merck’s CRISPR patents in rodent models
France-based biotechnology company genOway has acquired the exclusive global rights to German pharmaceutical company Merck Group’s CRISPR patents, to be used in the production and sale of rodent models.
FDA releases plan to boost biosimilars development
The US Food and Drug Administration has announced new measures to advance the development of biosimilar medicines.
Eli Lilly collaborates with AC Immune to develop Alzheimer’s treatment
Global pharmaceutical company Eli Lilly has entered into a licence and collaboration agreement with Swiss biotechnology company AC Immune.
AstraZeneca to launch CRISPR-based cancer research centre
Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.
Silence Therapeutics settles patent dispute with Alnylam
UK-based biotech company Silence Therapeutics has settled a patent dispute and entered into a licence agreement with Alnylam Pharmaceuticals.
Federal Circuit sends IP case back to USITC
The US Court of Appeals for the Federal Circuit partly reversed, vacated, and remanded a US International Trade Commission decision in a trade dress dispute on Friday, December 7.
Double victory for Novartis at Federal Circuit
The US Court of Appeals for the Federal Circuit has reversed one decision and affirmed another in two cases involving Novartis, with both judgments delivering victory to the Swiss pharmaceutical company.
Appeal filed against EPO sofosbuvir patent decision
Six organisations have appealed against the European Patent Office’s decision to uphold a patent for a key hepatitis C drug.
